Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.96 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.96 |
| ▸ | GAA | P10253 | 5/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.96 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.96 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide SCHEMBL9265511 | 0.98 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL8776888 | 0.98 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL9181146 | 0.98 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL14234116 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL15259344 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL18071930 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL20598257 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL22594950 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL23064754 | 0.98 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295917-A2 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | Tambo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-4192506-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | Tambo, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116056765-A | Trans-cyclooctene bioorthotics and uses in cancer and immunotherapy | 坦伯公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-110412285-B | Methods and compounds for inhibiting MCM protein complexes and their use in treating cancer | 香港科技大学 | 2022-11-15 | — | — | CN | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| CN-110412285-A | The method and compound of inhibition MCM albumen composition and its application in treating cancer | UNIV HONG KONG SCI & TECH | 2019-11-05 | — | — | CN | disclosed |
| CN-104736157-B | Methods and compounds for inhibiting MCM protein complexes and their use in treating cancer | 香港科技大学 | 2019-06-11 | — | — | CN | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2809686-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | Cerulean Pharma Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013116200-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2571525-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013025490-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2011146638-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | TOP2A 298/4885TOP2B 889/4885CYP3A4 3169/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TOP2A 541/4885TOP2B 704/4885CYP3A4 4765/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TOP2A 1988/4885TOP2B 2026/4885CYP3A4 3210/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TOP2A 541/4885TOP2B 704/4885CYP3A4 4765/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TOP2A 541/4885TOP2B 704/4885CYP3A4 4765/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TOP2A 541/4885TOP2B 704/4885CYP3A4 4765/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TOP2A 1988/4885TOP2B 2026/4885CYP3A4 3210/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TOP2A 1988/4885TOP2B 2026/4885CYP3A4 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.